Radiopharmaceutical Research Institute

Dr Ron Weiner

Position: Head ANSTO LifeSciencesRon Weiner

Phone: +61 (0)2 9717 9242

Email: ron.weiner@ansto.gov.au

 

Role at ANSTO:

Ron leads the scientific effort of the institute in generating and fostering innovation in research and development. He also leads the initiation, planning and execution of the research and development programmes of the Institute. Ron is responsible for the management process within the Institute, including; safety and regulatory compliance, staff performance management, project management and review, financial management and the development of the project portfolio and associated budget bid. As a member of the research management team led by the Chief of Research and contributes to the broader management and development of ANSTO through the work of this group.

Short Bio:

Ron has a PhD in bioinorganic chemistry and over 25 years experience in Hospital Nuclear Medicine, administration, medical education and research at 4 major United States Universities and the US National Institutes of Health. As the Director of the University of Connecticut Radiopharmacy, Ron introduced 8 new therapeutic and diagnostic radiopharmaceuticals. His basic research has focused on, the radiopharmacology and pharmacokinetics of the tumor and inflammation detection agent, 67Ga citrate and developing upregulated adhesion molecules as targets for inflammation detection. His clinical research has examined the efficacy and toxicity of therapeutic radiopharmaceuticals, Zevalin, Selective Internal Radiation spheres (90Y labeled Microspheres) and Quadramet.

Expertise:

SPECT Radiopharmaceuticals, Clinical Trials, Radiolabeling Chelation Technology, Radiopharmacy - GMP, Radiopharmacology, Radionuclides, Imaging, Biochemistry, Radiolabeling Monoclonal Antibodies.

Qualifications & Achievements:

  • Extensive publication record with 39 peer-reviewed publications, 14 book chapters (6 for major Nuclear Medicine Textbooks), over 50 short communication and conference proceedings and 32 invited presentations.
  • More than 20 years experience managing a hospital radiopharmacy.
  • Reviewer for the Journal of Nuclear Medicine and Reviewer, American Journal Roentgenology
  • Ad hoc member of US National Cancer Institute grant review study section subcommittee J
  • Principal Investigator and Co-investigator on 11 grants from Biogen Idec, Berlex, NIH and other agencies
  • Wide range of teaching experience with Nuclear Medicine and Radiology residents, Medical Students, Cardiology Fellows and Nuclear Medicine Technologists
  • Manuscript "App Rad Isot. 2002; 57:749-763" selected as an abstract in SomatoSelective distributed to Endocrinologist's offices

Key Publications:

Rowe BP, Weiner RE, Foster JE, et al. 90Yttrium microspheres for non-resectable liver cancer: The University of Connecticut Health Center Experience. Conn Med. 2007;17:523-528.

Weiner RE, Thakur ML. Radiolabeled Peptides in Oncology: Role in Diagnosis and Treatment. BioDrugs. 2005; 19:145-163.

Weiner RE, Thakur ML. "Radiopharmaceuticals" in: Diagnostic Nuclear Medicine. Sandler MP, Coleman RE, Wackers F and others, Editors, Baltimore, Lippincott, Williams & Wilkins, 4th edition; 2003:97-115.

Wei­ner RE, Sasso DE, Gionfriddo MA, Thrall RS, Syrbu S, Smilowitz HM, Vento J. Early detection of oleic acid-induced lung injury in rat using 111In-labeled antibody directed against intercellular adhesion molecule-1. J Nucl Med. 2001; 42:1109-1115.

Weiner RE. The mechanism of 67Ga localization in malignant tissue. Nucl Med Biol. 1996; 23:745-751.